Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors

Rigel Pharmaceuticals (RIGL) announced an update on their ongoing clinical study.

Rigel Pharmaceuticals is running a new Phase 4 study called “A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib.” The goal is to see how olutasidenib interacts with other common drugs in patients with cancers such as AML, glioma, cholangiocarcinoma, and other solid tumors.

The main treatment is olutasidenib, an oral drug already used in certain IDH1 mutation blood cancers. The study also gives small test doses of several standard “probe” drugs to see how olutasidenib may change how other medicines are processed in the body.

The trial uses a single group of patients who all receive olutasidenib plus the probe drugs, so there is no comparison arm. It is open-label, meaning both doctors and patients know what is given, and the focus is on understanding drug interactions rather than proving basic safety or cancer benefit.

Olutasidenib is given twice a day from Day 5 to Day 22, with an option to extend treatment to Day 64 for more data. Patients receive the probe drug cocktail once before starting olutasidenib and again after they reach steady levels of the Rigel drug.

The study was first submitted on March 12, 2026, which signals when Rigel formally moved forward with this design. The last update on March 17, 2026, shows the record is active and reflects the latest protocol details.

The trial is currently listed as recruiting, meaning enrollment is under way but early. The primary and final completion dates are not yet posted, so investors should assume data will take time and likely emerge in stages.

For investors, this update supports Rigel’s push to deepen the profile of olutasidenib and make it easier for doctors to use it with other drugs in complex cancer patients. Clear drug-interaction data can expand real-world use, reduce physician hesitation, and support label refinements, which can all help sentiment around RIGL over the medium term.

In the broader oncology space, competitors with targeted IDH1 drugs will watch how clean the interaction profile looks, since fewer interactions can be a commercial edge in very sick patients. While near-term revenue impact is limited, steady clinical investment like this often underpins longer-term valuation and may support the stock if data are positive and safety remains solid.

The study is currently ongoing and updated, with more operational details available on the ClinicalTrials.gov portal under the listed NCT number.

To learn more about RIGL’s potential, visit the Rigel Pharmaceuticals drug pipeline page.